LC
NKTR icon

Lindbrook Capital’s Nektar Therapeutics NKTR Stock Holding History

Lindbrook Capital’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6
Closed – – 2945
2022
Q3 		$0 Sell
6
-40
-87% -$2.38K ﹤0.01% 2815
2022
Q2 		$3K Sell
46
-47
-51% -$2.96K ﹤0.01% 1810
2022
Q1 		$8K Buy
93
+91
+4,550% +$13.5K ﹤0.01% 1387
2021
Q4 		$0 Buy
+2
New +$434 ﹤0.01% 2167

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Lindbrook Capital's NKTR Position: Q4 2022 in Review

Lindbrook Capital sold out of Nektar Therapeutics (NKTR) in Q4 2022, closing a stake of 6 shares.

Lindbrook Capital first reported a position in NKTR in Q4 2021 and held it in 4 quarters. The position peaked at $8K in Q1 2022. 214 funds tracked by Wall St. Rank hold NKTR as of Q4 2022.

  • Lindbrook Capital reported no remaining Nektar Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Lindbrook Capital sold 6 Nektar Therapeutics shares in Q4 2022.
  • Lindbrook Capital first reported a position in Nektar Therapeutics in Q4 2021 and held it in 4 quarters.
  • Lindbrook Capital's Nektar Therapeutics position peaked at $8K in Q1 2022.
  • 214 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2022.

Based on Lindbrook Capital's 13F filing for Q4 2022, filed 25 Jan 2023.